Literature DB >> 12781883

International prospective evaluation of scintimammography with (99m)technetium sestamibi.

Fotini S Sampalis1, Ronald Denis, Daniel Picard, David Fleiszer, Ginette Martin, Edgard Nassif, John S Sampalis.   

Abstract

BACKGROUND: The purpose of this study is to evaluate the efficacy of scintimammography with (99m)Technetium-Sestamibi for the diagnosis of breast cancer.
METHODS: This was a multicenter prospective cohort clinical trial. A total of 1,734 women were enrolled of whom 1,243 had complete data upon study completion.
RESULTS: The mean +/- standard error age of the patients is 56 +/-12 years (with a range of 19 to 94). Mammographic results were classified by the Breast Imaging Reporting and Data System (BIRADS) as 199 (16%) BIRADS 5, 149 (12%) BIRADS 4, 199 (16%) BIRADS 3, and 696 (56%) BIRADS 2 or 1. Scintimammography was positive for 322 (26%) of the patients and negative for 921 (76%). Histopathology showed malignancy for 201 (16%) of the patients. Sensitivity and specificity of scintimammography was estimated 93% and 87% respectively. A positive predictive value (PPV) of 58% with a negative predictive value of 98% were calculated.
CONCLUSIONS: The present study suggests that scintimammography with (99m)Technetium-Sestamibi is highly accurate for the detection of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12781883     DOI: 10.1016/s0002-9610(03)00077-1

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  8 in total

Review 1.  Nuclear imaging of the breast: translating achievements in instrumentation into clinical use.

Authors:  Carrie B Hruska; Michael K O'Connor
Journal:  Med Phys       Date:  2013-05       Impact factor: 4.071

Review 2.  Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies.

Authors:  Laleh Amiri-Kordestani; Agnes Basseville; Karen Kurdziel; Antonio Tito Fojo; Susan E Bates
Journal:  Drug Resist Updat       Date:  2012-03-29       Impact factor: 18.500

3.  Added value of semi-quantitative breast-specific gamma imaging in the work-up of suspicious breast lesions compared to mammography, ultrasound and 3-T MRI.

Authors:  T Meissnitzer; A Seymer; P Keinrath; J Holzmannhofer; C Pirich; K Hergan; M W Meissnitzer
Journal:  Br J Radiol       Date:  2015-04-17       Impact factor: 3.039

4.  Breast scintigraphy today: indications and limitations.

Authors:  Orazio Schillaci; John R Buscombe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-23       Impact factor: 9.236

5.  Comparison of 99mTc-MIBI scintigraphy, ultrasound, and mammography for the diagnosis of BI-RADS 4 category lesions.

Authors:  Hongbiao Liu; Hongwei Zhan; Da Sun
Journal:  BMC Cancer       Date:  2020-05-24       Impact factor: 4.430

6.  99mTc-thymine scintigraphy may be a promising method in the diagnosis of breast cancer.

Authors:  Monica Pires Ribeiro; Sergio Augusto Lopes de Souza; Flavia Paiva Proença Lobo Lopes; Paulo Henrique Rosado-de-Castro; Lea Mirian Barbosa da Fonseca; Bianca Gutfilen
Journal:  Clinics (Sao Paulo)       Date:  2013       Impact factor: 2.365

Review 7.  Imaging and cancer: a review.

Authors:  Leonard Fass
Journal:  Mol Oncol       Date:  2008-05-10       Impact factor: 7.449

8.  Validity of breast-specific gamma imaging for Breast Imaging Reporting and Data System 4 lesions on mammography and/or ultrasound.

Authors:  Min Jeng Cho; Jung-Hyun Yang; Yeong Beom Yu; Kyoung Sik Park; Hyun Woo Chung; Young So; Nami Choi; Mi Young Kim
Journal:  Ann Surg Treat Res       Date:  2016-03-30       Impact factor: 1.859

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.